Repositioning Candidate Details
| Candidate ID: | R1068 |
| Source ID: | DB06642 |
| Source Type: | investigational |
| Compound Type: | biotech |
| Compound Name: | Bevasiranib |
| Synonyms: | Bevasiranib |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | Bevasiranib is a small interfering RNA (siRNA) targeting vascular endothelial growth factor A (VEGF-A). |
| CAS Number: | 959961-96-7 |
| Molecular Weight: | |
| DrugBank Indication: | Investigated for use/treatment in macular degeneration and diabetic retinopathy. |
| DrugBank Pharmacology: | Bevasiranib represents the first drug in a promising new class of experimental medical treatments. It is a small interfering RNA (siRNA) drug, which silences the genes that produce Vascular Endothelial Growth Factor (VEGF), a protein that promotes blood vessel growth. The treatment slows the growth and leakage of abnormal blood vessels that are associated with the wet form of macular degeneration. The drug is injected directly into the eye. |
| DrugBank MoA: | -- |
| Targets: | Vascular endothelial growth factor A |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|